论文部分内容阅读
采用99mTc -MIBI经直肠给药测定 5 4例肝硬化患者各组肝功能的心 /肝 (H/L)比值及门静脉压力 (PVP) ,结果Child -A、B、C级各组H/L分别为 0 .4 9± 0 .18(2 1)、0 .6 9± 0 .16 (15 )、0 .91± 0 .2 1(18) ;PVP分别为 2 .2 2± 0 .5 7(2 1)kPa、2 .85± 0 .38(15 )kPa及 3.5 4± 0 .6 5 (18)kPa。而对照组的H/L及PVP分别为 0 .30± 0 .12 (16 )kPa及 1.6 1± 0 .384 6kPa。Child -A、B、C级各组分别与对照组及各组之间用t检验比较 ,除Child -B与C级组PVP无显著性差异 (P >0 .0 5 )外 ,其余均有非常显著性差异 (P <0 .0 0 1)及显著性差异 (P <0 .0 5 )。对 16例肝硬化患者治疗前后H/L及PVP进行测定 ,服药前、后H/L分别为 0 .73± 0 .16 (16 )及 0 .4 7± 0 .18(16 ) ;门脉压力分别为3.0 0± 0 .5 5 (16 )kPa及 2 .2 0± 0 .6 2 (16 )kPa ,作配对t检验 ,结果治疗前后H/L及PVP差异非常显著。本法测定门脉压力方便 ,无创伤 ,病人能接受 ,而且可分析病情 ,判断疗效 ,对指导制订治疗方案 ,估计预后等均有独特价值
The heart / liver (H / L) ratio and portal vein pressure (PVP) of liver function in 54 patients with cirrhosis were determined by rectal administration of 99mTc -MIBI. Results The levels of H / L in Child-A, Respectively, 0.49 ± 0.18 (2 1), 0.69 ± 0.16 (15), 0.91 ± 0.21 (18); PVP were2.22 ± 0.5 7 (2 1) kPa, 2.85 ± 0.38 (15) kPa, and 3.5 4 ± 0.65 (18) kPa. While the H / L and PVP in the control group were respectively 0.30 ± 0.12 (16) kPa and 1.6 1 ± 0.384 6kPa. Child-A, B, C groups were compared with the control group and each group by t test, except for Child-B and C-level PVP no significant difference (P> 0.05), the rest have There were significant differences (P <0.001) and significant differences (P <0.05). The levels of H / L and PVP in 16 patients with cirrhosis before and after treatment were measured. The H / L before and after treatment were 0 .73 ± 0 .16 (16) and 0. 47 ± 0. 18 (16) The pressures were 3.0 0 ± 0.55 (16) kPa and 2.020 ± 0.662 (16) kPa, respectively, for the paired t-test, the results before and after treatment H / L and PVP difference was significant. This method of portal pressure measurement is convenient, noninvasive, the patient can accept, and can analyze the condition, to determine the efficacy of guiding the development of treatment options, prognosis, etc. have a unique value